Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2

EBioMedicine

Peter Nilsson¹  Max Gordon²  Ulrika Marking³  Ann-Christin Salomonsson³  Nina Greilert-Norin³  Sebastian Havervall³  Cecilia Hellström³  Henry Ng³  Jonas Klingström⁴  Mia Phillipson⁵  Mikael Åberg⁶  Elisa Pin⁶  Kim Blom⁶  Charlotte Thålin⁶  Sara Mangsbo⁷  Sophia Hober⁷ 

[1] Centre for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden;Department of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden;Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden;Department of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden;Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden;Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden;Public Health Agency of Sweden, Solna, Sweden;

关键词: SARS-CoV-2;    Neutralizing antibody response;    Prior infection;    ChAdOx1 nCoV-19;    BNT162b2 vaccine;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: Recent reports demonstrate robust serological responses to a single dose of messenger RNA (mRNA) vaccines in individuals previously infected with SARS-CoV-2. Data on immune responses following a single-dose adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein (ChAdOx1 nCoV-19) in individuals with previous SARS-CoV-2 infection are however limited, and current guidelines recommend a two-dose regimen regardless of preexisting immunity. Methods: We compared RBD-specific IgG and RBD-ACE2 blocking antibodies against SARS-CoV-2 wild type and variants of concern following two doses of the mRNA vaccine BNT162b2 in SARS-CoV-2 naïve healthcare workers (n=65) and a single dose of the adenovector vaccine ChAdOx1 nCoV-19 in 82 healthcare workers more than (n=45) and less than (n=37) 11 months post mild SARS-CoV-2 infection at time of vaccination. Findings: The post-vaccine levels of RBD-specific IgG and neutralizing antibodies against the SARS-CoV-2 wild type and variants of concern including Delta lineage 1.617.2 were similar or higher in participants receiving a single dose of ChAdOx1 nCoV-19 vaccine post SARS-CoV-2 infection (both more than and less than 11 months post infection) compared to SARS-CoV-2 naïve participants who received two doses of BNT162b2 vaccine. Interpretation: Our data support that a single dose ChAdOx1 nCoV-19 vaccine that is administered up to at least 11 months post SARS-CoV-2 infection serves as an effective immune booster. This provides a possible rationale for a single-dose vaccine regimen. Funding: A full list of funding bodies that contributed to this study can be found in the Acknowledgements section

【 授权许可】

Unknown